IN SB0272

Allows pharmacists to substitute FDA-approved interchangeable biosimilar products for prescribed biological products when the prescriber indicates "May substitute" and the pharmacist notifies both the customer and prescriber within 5 calendar days

Defines biological products to include viruses, vaccines, blood products, therapeutic serums, toxins, antitoxins, proteins, and allergenic products used for human disease prevention or treatment

Requires the Indiana Board of Pharmacy to maintain a public website listing biosimilar products determined by the FDA to be interchangeable, with authority to adopt implementing rules

Mandates pharmacies and prescribers retain records of interchangeable biosimilar substitutions for at least 5 years

Directs the Health Finance Commission to study during 2013: expansion of the INSPECT prescription monitoring program, use of methadone and opioids in treatment programs, and how Indiana law should address prescribing and substituting biosimilar products